BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1070 related articles for article (PubMed ID: 2115060)

  • 1. A new test for the diagnosis of growth hormone deficiency due to primary pituitary impairment: combined administration of pyridostigmine and growth hormone-releasing hormone.
    Ghigo E; Imperiale E; Boffano GM; Mazza E; Bellone J; Arvat E; Procopio M; Goffi S; Barreca A; Chiabotto P
    J Endocrinol Invest; 1990 Apr; 13(4):307-16. PubMed ID: 2115060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of cholinergic tone by pyridostigmine promotes both basal and growth hormone (GH)-releasing hormone-induced GH secretion in children of short stature.
    Ghigo E; Mazza E; Imperiale E; Rizzi G; Benso L; Müller EE; Camanni F; Massara F
    J Clin Endocrinol Metab; 1987 Sep; 65(3):452-6. PubMed ID: 3114300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatostatin pretreatment enhances growth hormone (GH) responsiveness to GH-releasing hormone: a potential new diagnostic approach to GH deficiency.
    Tzanela M; Guyda H; Van Vliet G; Tannenbaum GS
    J Clin Endocrinol Metab; 1996 Jul; 81(7):2487-94. PubMed ID: 8675565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reliability of provocative tests to assess growth hormone secretory status. Study in 472 normally growing children.
    Ghigo E; Bellone J; Aimaretti G; Bellone S; Loche S; Cappa M; Bartolotta E; Dammacco F; Camanni F
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3323-7. PubMed ID: 8784091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic studies with intravenous and intranasal growth hormone-releasing peptide-2 in children of short stature.
    Pihoker C; Middleton R; Reynolds GA; Bowers CY; Badger TM
    J Clin Endocrinol Metab; 1995 Oct; 80(10):2987-92. PubMed ID: 7559885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of growth hormone-releasing effect of growth hormone-releasing hormone, clonidine and pyridostigmine in normal children and adolescents. GH-releasing effect of GHRH, clonidine and pyridostigmine.
    Ghigo E; Arvat E; Nicolosi M; Mazza E; Camanni F
    Panminerva Med; 1990; 32(1):1-3. PubMed ID: 2263395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth hormone response to hexarelin, growth hormone-releasing hormone plus pyridostigmine and arginine plus estrogen in prepubertal and early pubertal short children.
    Guzzaloni G; Grugni G; Morabito F
    Minerva Endocrinol; 1998 Dec; 23(4):99-104. PubMed ID: 10361807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hexarelin-induced growth hormone response in short stature. Comparison with growth hormone-releasing hormone plus pyridostigmine and arginine plus estrogen.
    Guzzaloni G; Grugni G; Morabito F
    J Endocrinol Invest; 1999 May; 22(5):360-8. PubMed ID: 10401710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth hormone (GH) response to combined pyridostigmine and GH-releasing hormone administration in patients with Prader-Labhard-Willi syndrome.
    Cappa M; Grossi A; Borrelli P; Ghigo E; Bellone J; Benedetti S; Carta D; Loche S
    Horm Res; 1993; 39(1-2):51-5. PubMed ID: 8406340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of the pituitary GH releasable pool in short children with GH neurosecretory dysfunction.
    Aimaretti G; Bellone S; Bellone J; Chiabotto P; Baffoni C; Corneli G; Origlia C; de Sanctis C; Camanni F; Ghigo E
    Clin Endocrinol (Oxf); 2000 Mar; 52(3):287-93. PubMed ID: 10718826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GH response to GHRH combined with pyridostigmine or arginine in different conditions of low somatotrope secretion in adulthood: obesity and Cushing's syndrome in comparison with hypopituitarism.
    Procopio M; Maccario M; Savio P; Valetto MR; Aimaretti G; Grottoli S; Oleandri SE; Baffoni C; Tassone F; Arvat E; Camanni F; Ghigo E
    Minerva Endocrinol; 1999; 24(3-4):107-11. PubMed ID: 10953725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retesting young adults with childhood-onset growth hormone (GH) deficiency with GH-releasing-hormone-plus-arginine test.
    Aimaretti G; Baffoni C; Bellone S; Di Vito L; Corneli G; Arvat E; Benso L; Camanni F; Ghigo E
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3693-9. PubMed ID: 11061526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of exogenous growth hormone pretreatment on the pituitary growth hormone response to growth hormone-releasing hormone alone or in combination with pyridostigmine in type I diabetic patients.
    Giustina A; Bossoni S; Bodini C; Cimino A; Pizzocolo G; Schettino M; Wehrenberg WB
    Acta Endocrinol (Copenh); 1991 Nov; 125(5):510-7. PubMed ID: 1759540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GH response to GHRH combined with pyridostigmine or arginine in different conditions of low somatotrope secretion in adulthood: obesity and Cushing's syndrome in comparison with hypopituitarism.
    Procopio M; Maccario M; Savio P; Valetto MR; Aimaretti G; Grottoli S; Oleandri SE; Baffoni C; Tassone F; Arvat E; Camanni F; Ghigo E
    Panminerva Med; 1998 Mar; 40(1):13-7. PubMed ID: 9573747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of acute and chronic growth hormone (GH) administration on GH secretion in patients with idiopathic GH deficiency.
    Hanew K; Goh M; Sato S; Shimizu Y; Sasaki A; Aida M; Yoshinaga K
    J Clin Endocrinol Metab; 1988 Apr; 66(4):715-21. PubMed ID: 3126213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low hexarelin dose and pyridostigmine have additive effect and potentiate to the same extent the GHRH-induced GH response in man.
    Arvat E; Di Vito L; Ramunni J; Gianotti L; Giordano R; Deghenghi R; Camanni F; Ghigo E
    Clin Endocrinol (Oxf); 1997 Oct; 47(4):495-500. PubMed ID: 9404449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis of growth hormone (GH) deficiency in adults with hypothalamic-pituitary disorders: comparison of test results using pyridostigmine plus GH-releasing hormone (GHRH), clonidine plus GHRH, and insulin-induced hypoglycemia as GH secretagogues.
    Hoeck HC; Vestergaard P; Jakobsen PE; Falhof J; Laurberg P
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1467-72. PubMed ID: 10770183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Further evidence of cholinergic impairment of the neuroendocrine control of the GH secretion in Down's syndrome.
    Beccaria L; Marziani E; Manzoni P; Arvat E; Valetto MR; Gianotti L; Ghigo E; Chiumello G
    Dement Geriatr Cogn Disord; 1998; 9(2):78-81. PubMed ID: 9524798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reevaluation of growth hormone (GH) secretion in 69 adults diagnosed as GH-deficient patients during childhood.
    Longobardi S; Merola B; Pivonello R; Di Rella F; Di Somma C; Colao A; Ghigo E; Camanni F; Lombardi G
    J Clin Endocrinol Metab; 1996 Mar; 81(3):1244-7. PubMed ID: 8772606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The growth hormone response to pyridostigmine plus growth hormone releasing hormone is not influenced by pubertal maturation.
    Cappa M; Loche S; Salvatori R; Faedda A; Borrelli P; Cella SG; Pintor C; Müller EE
    J Endocrinol Invest; 1991 Jan; 14(1):41-5. PubMed ID: 2045624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.